US 12,391,745 B2
Adeno-associated virus antibodies and fragments thereof
Sohrab Khan, Cambridge, MA (US); Danielle Griffin, Cambridge, MA (US); and Louise Rodino-Klapac, Cambridge, MA (US)
Assigned to Sarepta Therapeutics, Inc., Cambridge, MA (US)
Filed by Sarepta Therapeutics, Inc., Cambridge, MA (US)
Filed on Jun. 15, 2021, as Appl. No. 17/348,356.
Claims priority of provisional application 63/038,957, filed on Jun. 15, 2020.
Prior Publication US 2021/0388064 A1, Dec. 16, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/08 (2006.01); A01K 67/027 (2024.01); G01N 33/53 (2006.01); G01N 33/543 (2006.01)
CPC C07K 16/081 (2013.01) [C07K 16/08 (2013.01); G01N 33/53 (2013.01); G01N 33/54306 (2013.01); A01K 67/027 (2013.01); A01K 2217/05 (2013.01); C07K 2317/33 (2013.01); C07K 2317/56 (2013.01)] 14 Claims
 
1. An isolated anti-AAV (adeno-associated virus) antibody or antigen-binding fragment thereof capable of specifically binding an epitope of an AAV capsid protein, wherein the epitope comprises an amino acid sequence QGAGKDNVDYSS (SEQ ID NO: 45); and wherein the antibody or antigen binding fragment thereof comprises:
a. a heavy chain variable region comprising an amino acid sequence that is identical to the amino acid sequence set forth in SEQ ID NO: 1; and a light chain variable region comprising an amino acid sequence that is identical to the amino acid sequence set forth in SEQ ID NO: 2;
b. a heavy chain variable region comprising an amino acid sequence that is identical to the amino acid sequence set forth in SEQ ID NO: 5; and a light chain variable region comprising an amino acid sequence that is identical to the amino acid sequence set forth in SEQ ID NO: 6;
c. a heavy chain variable region comprising an amino acid sequence that is identical to the amino acid sequence set forth in SEQ ID NO: 13; and a light chain variable region comprising an amino acid sequence that is identical to the amino acid sequence set forth in SEQ ID NO: 14;
d. a heavy chain variable region comprising an amino acid sequence that is identical to the amino acid sequence set forth in SEQ ID NO: 9; and a light chain variable region comprising an amino acid sequence that is identical to the amino acid sequence set forth in SEQ ID NO: 10; or
e. a heavy chain variable region comprising an amino acid sequence that is identical to the amino acid sequence set forth in SEQ ID NO: 17; and a light chain variable region comprising an amino acid sequence that is identical to the amino acid sequence set forth in SEQ ID NO: 18.